Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
